Effect of taurine on Ca,Mg-ATPase activity and platelet aggregation in man

Taurine and Its Derivatives: Analysis of the Inhibitory Effect on Platelet Function and Their Antithrombotic Potential

“…Taurine incubation (25 nM) with human PRP resulted in a decrease of both spontaneous and induced (by 3.5 µM ADP) platelet aggregation rate, in the taurine treated platelets vs. control platelets (1.0 ± 0.3 vs. 2.1 ± 0.6, and 30.3 ± 5.8 vs. 62.8 ± 9.8, respectively). In the same in vitro study, taurine (25 mM) was also shown to enhance platelet Ca, Mg-ATPase activity by 45%, an effect proven to be mediated through the stimulatory action of taurine on calmodulin [140] (Table 2).…”

“…There is a growing body of evidence depicting the influence of taurine on human platelet function, confirming the encouraging outcomes from animal studies. Almazov et al (1985) was one of the first to describe the effect of taurine on platelet aggregation, and to underline a possible mechanism of its action. Taurine incubation (25 nM) with human PRP resulted in a decrease of both spontaneous and induced (by 3.5 µM ADP) platelet aggregation rate, in the taurine treated platelets vs. control platelets (1.0 ± 0.3 vs. 2.1 ± 0.6, and 30.3 ± 5.8 vs. 62.8 ± 9.8, respectively).…”

“…Still far from being elucidated, the potential mechanisms underlying the overall inhibitory influence of taurine and its derivatives on platelet activity can be summarized as follows: decreased platelet TxA 2 [41] and TxB 2 production [113]; suppression of platelet cyclooxygenase activity [144,158]; stimulation of calmodulin-mediated platelet Ca, Mg-ATPase activity [140,162], attenuation of platelet Ca 2+ influx [141,154] and suppression of intraplatelet Ca 2+ response to activating agonists [156]; platelet stabilization against PAF [126,143,156]; suppression of β-TG and ATP release response to agonists, as markers of discharge from alpha and dense platelet granules [154]; preservation of platelet glutathione pool [113]; increased affinity of covalent inhibitors (e.g., DT, PCT, IPCT) to molecular targets, i.e., sulfur-containing groups on platelet surface (such might be the thiol group of P2Y 12 ADP receptor) [135][136][137][138][139]; and pronounced enhancement of hydrogen sulfide (H 2 S) plasma level [163][164][165][166], H 2 S being known to inhibit platelet activation and aggregation [167][168][169][170][171][172]. Taurine may also interfere with platelet activity by generating complementary processes such as an increase of the endothelial NO release [173][174][175][176], decrease of epinephrine and norepinephrine circulant level [177][178][179], suppression of CD147-dependent M...…”

Effect of chronic administration of anabolic androgenic steroids and taurine on platelet aggregation in rats

“…In human studies, similar data have been reported. Daily supplemented diets with taurine showed an increased resistance to aggregation by 30-70% (6), while in vitro pre-incubation of platelets with taurine demonstrated a decrease in platelet aggregation with up to 50% (28,29).…”

“…Several mechanisms have been proposed to explain the platelet modulatory action of taurine, such as reduced production of TBX A2, B2 (6,25), increased generation of PG I2 (34), reduced effects of PAF (35), increased activity of platelet's Ca/Mg ATP-ase and the attenuation of the platelet calcium influx induced by aggregating agonists (7,28). Due to all these actions, taurine has been thought to be helpful in the prevention of the cardiovascular disease and only the lack of large-scale phase 3 clinical trials stops providing taurine as a therapeutic agent (23,36).…”